Drugs / BGB-DXP604
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04669262 | Dec 2020 → May 2021 | — | BeiGene | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-DXP604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04669262 ↗ |
| Route | Intravenous | “Administered as intravenous (IV) infusion over 30 to 60 minutes” NCT04669262 ↗ |